Mark Lackner News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Mark Lackner. Real-time updates on events, politics, business and more.

Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates

November 7, 2023

Company on track for first NDA submission in a gynecologic malignancy in 2026 with a cash balance of $517 million

Mark Lackner Zentalis Pharmaceuticals Inc Company Performance Analysis Company Performance Chief Translational Officer Kevin Bunker

Source: yahoo.com

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

November 6, 2023

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...

United States New York San Diego Kimberly Blackwell Mark Lackner Program Updates

Source: marketscreener.com

Zentalis Pharmaceuticals Shares Hit All-Time Low

November 6, 2023

By Dean Seal Shares of Zentalis Pharmaceuticals fell to an all-time low after its co-founder said he would step down as chief scientific officer and the...

Mark Lackner Zentalis Pharmaceuticals Kevin Bunker Dean Seal Article Normal Biotechnology Services

Source: marketwatch.com

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

April 17, 2023

Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy... | April 17, 2023

United States San Diego New York Julia Deutsch Mark Lackner Alexandra Roy